Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery

Summary

Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems.

Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI \> 35 kg/m2). Clinical and research evidence shows that shortly after RYGB, T2DM resolves with improving glucose tolerance. Foregut hypothesis behind bariatric surgeries postulate, that bypassed portions of intestine contain a substance, that acts as an anti-incretin, ie. to counteract metabolically favourable incretins. In view of the recent studies, it may be that GIP is really the anti-incretin behind this hypothesis.

The current study is conducted to investigate the vasoactive roles of the GIP. The investigators aim to show that GIP is the major contributor to the blood flow and tissue blood volume observed in postprandial state.

Conditions

• Type 2 Diabetes
• Obesity

Interventions

PROCEDURE

Roux-en-Y

Subjects in the intervention group will be divided into two consecutive surgical groups, RYGB or SG. After the surgery, subjects are controlled in hospital ward for approximately three days.

DRUG

GIP-infusion

Blood flow and volume during infusion

DRUG

GLP-1

Blood flow and volume during infusion

DRUG

MMS

Blood flow and volume after meal solution

PROCEDURE

Sleeve gastrectomy

as in RYGS group

Sponsors & Collaborators

• Lund University

  collaborator OTHER

• Turku University Hospital

  lead OTHER_GOV

Principal Investigators

• Pirjo Nuutila, Prof · PET centre, Turku

Study Design

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2013-01-31

Primary Completion

2015-11-30

Completion

2016-01-31

Countries

• Finland

Study Locations